CHARM Therapeutics, a 3D deep-learning research company discovering and developing transformational medicines founded by David Baker, Ph.D. and Laksh Aithani, announces today a $50M Series A financing co-led by F-Prime Capital and OrbiMed. CHARM Therapeutics is pioneering 3D deep-learning to discover and develop transformational medicines against previously hard-to-drug targets. The Company’s proprietary platform, DragonFold, applies expertise in protein-ligand co-folding to deliver transformational medicines targeting challenging molecular targets in cancer and other disease areas. Source: Charm press release 9/6/22